Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
WallStPal · PDF guide
TARS Insider Trading: Insider Buys and Sells · https://wallstpal.com/stock/tars/insider-trading/ · saved 2026-10-28

About this page

Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.

How to read it

Form 4
The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
Buy (P) and Sell (S)
Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
Value
Shares times price, as reported on the filing.
10b5-1
A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
Late filing
A Form 4 filed more than two business days after the trade.
Vs. S&P 500
How the stock did after the trade minus how the overall market did in the same weeks.

A real example

In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.

Explain it like I'm 13

If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.

Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.

Summarize with AIChatGPTClaudePerplexityGoogle AIGrokCopilot
Insider tradingForm 4

Tarsus Pharmaceuticals, Inc. (TARS) Insider Trading

13 open-market trades reported since Jun 17, 2026: 0 purchases worth $0 and 13 sales worth $7.65M.

By insider

InsiderRoleBuysBoughtSellsSoldLatest
William J. Phd LinkDirector0$02$1.76MSep 17, 2026
Elizabeth Yeu LinChief Medical Officer0$05$2.12MSep 9, 2026
Bobak R. AzamianCEO0$03$2.32MSep 9, 2026
Seshadri NeervannanCOO0$01$388KSep 9, 2026
Jeffrey S. FarrowSee Remarks0$01$877KJun 17, 2026
Katherine GoodrichDirector0$01$183KJun 17, 2026

All trades

TARS insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHolding3 mo. afterFiling
Sep 17Sep 15William J. Phd LinkDirectorDirector▼ SELL10b5-112,50078.38$980K−12%Form 4 ↗
Sep 9Sep 4Elizabeth Yeu LinChief Medical OfficerChief Medical Officer▼ SELL10b5-110,77387.50$943K−81%Form 4 ↗
Sep 9Sep 4Bobak R. AzamianCEOCEO (ind.)▼ SELL10b5-110,00090.56$906K−1.2%Form 4 ↗
Sep 9Sep 4Seshadri NeervannanCOOCOO▼ SELL10b5-14,56485.00$388K−5.5%Form 4 ↗
Sep 9Sep 4Elizabeth Yeu LinChief Medical OfficerChief Medical Officer (ind.)▼ SELL10b5-13,18087.50$278K−67%Form 4 ↗
Sep 3Sep 2Bobak R. AzamianCEOCEO (ind.)▼ SELL10b5-110,00080.06$801K−1.2%Form 4 ↗
Sep 3Sep 2Elizabeth Yeu LinChief Medical OfficerChief Medical Officer▼ SELL10b5-15,38780.00$431K−29%Form 4 ↗
Sep 3Sep 1Elizabeth Yeu LinChief Medical OfficerChief Medical Officer▼ SELL10b5-14,60173.86$340K−20%Form 4 ↗
Sep 3Sep 2Elizabeth Yeu LinChief Medical OfficerChief Medical Officer (ind.)▼ SELL10b5-11,59080.00$127K−25%Form 4 ↗
Jun 22Jun 17Bobak R. AzamianCEOCEO (ind.)▼ SELL10b5-110,00061.55$615K−1.2%Form 4 ↗
Jun 17Jun 16Jeffrey S. FarrowSee RemarksSee Remarks▼ SELL14,39660.95$877K−20%Form 4 ↗
Jun 17Jun 15William J. Phd LinkDirectorDirector▼ SELL10b5-112,50062.12$776K−11%Form 4 ↗
Jun 17Jun 15Katherine GoodrichDirectorDirector▼ SELL10b5-12,95462.08$183K−57%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings